Buy Rating Affirmed for Halozyme on OCREVUS SC Prospects and Enhanze Technology Potential
TipRanks (Wed, 17-Apr 10:55 AM ET)
Analysts Are Bullish on Top Healthcare Stocks: Halozyme (HALO), Cognition Therapeutics (CGTX)
TipRanks (Tue, 16-Apr 7:41 AM ET)
Halozyme to Participate in Upcoming Investor Conferences
PRNewswire (Tue, 27-Feb 8:30 AM ET)
HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS
PRNewswire (Tue, 20-Feb 4:01 PM ET)
Halozyme To Report Fourth Quarter and Full Year 2023 Financial and Operating Results
PRNewswire (Thu, 8-Feb 4:30 PM ET)
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.
Halozyme Therapeutics trades on the NASDAQ stock market under the symbol HALO.
As of April 19, 2024, HALO stock price climbed to $38.64 with 965,872 million shares trading.
HALO has a beta of 1.21, meaning it tends to be more sensitive to market movements. HALO has a correlation of 0.20 to the broad based SPY ETF.
HALO has a market cap of $4.90 billion. This is considered a Mid Cap stock.
Last quarter Halozyme Therapeutics reported $230 million in Revenue and $.82 earnings per share. This fell short of revenue expectation by $-3 million and missed earnings estimates by -$.01.
In the last 3 years, HALO stock traded as high as $59.46 and as low as $29.85.
The top ETF exchange traded funds that HALO belongs to (by Net Assets): VTI, IJH, VB, IWM, VXF.
HALO stock has underperformed the market in the last year with a return of +8.2%, while SPY returned +21.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in HALO shares. However, HALO has outperformed the market in the last 3 month and 2 week periods, returning +10.6% and -2.7%, while SPY returned +4.3% and -3.5%, respectively. This indicates HALO has been having a stronger performance recently.
HALO support price is $37.10 and resistance is $38.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that HALO stock will trade within this expected range on the day.